Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor
Imatinib mesylate, as treatment for gastrointestinal stromal tumors (GIST), has dramatically changed the prognosis for survival – not only because it is efficacious, but also because it attracted attention to this malignant disease. GIST is now a well-known disease entity and a paradigm for targeted...
Main Authors: | Silke Cameron, Inga-Marie Schaefer, Harald Schwoerer, Giuliano Ramadori |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2011-10-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/333471 |
Similar Items
-
Surgical intervention of a giant gastric gastrointestinal stromal tumor following neoadjuvant therapy with imatinib
by: Chien-Yang Wang, et al.
Published: (2018-01-01) -
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
by: Chaoyong Shen, et al.
Published: (2014-11-01) -
Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
by: Xiangchen Hu, et al.
Published: (2022-09-01) -
Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
by: Wen-Kuan Huang, et al.
Published: (2020-05-01) -
Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
by: Shang-Yu Wang, et al.
Published: (2019-03-01)